Healio

Qlaris Bio initiates trials for potassium channel modulator therapy in glaucoma patients

Please provide your email address to receive an email when new articles are posted on . The Osprey and Apteryx trials will assess QLS-111, a potassium channel modulator, in patients with glaucoma. The ...
News Medical

Metrion Biosciences and The KCNC1 Foundation Collaborate on New Ion Channel Modulators

Variants of the KCNC1 gene impact K v 3.1 potassium channel function, resulting in neurodevelopmental disorders which can include progressive myoclonic epilepsy (PME) and developmental epileptic ...
Business Wire

Cavion’s T-Type Calcium Channel Modulator CX-8998 is Superior to Current Standard of Care in Suppressing Absence Seizures in a Genetic Epilepsy Model

CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cavion, Inc., a clinical stage biotechnology company developing novel therapeutics for neurological diseases, announced today that their first ...
Fox 5 San Diego

Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome

LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of ...